Wave Life Sciences stock fell 2.58 percent as FDA path advances
Published on 10/04/2026 at 23:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Wave Life Sciences stock (ISIN US94352A1043) was last at USD 3.78 on Nasdaq on October 2, 2026, down 2.58 percent from the prior session. The move followed a new regulatory pathway for WVE-006, as GlobeNewswire reported on October 1, 2026. For investors, the key question is whether the trial design can shorten the route from biomarker data to a regulatory filing.
FDA backs a two-year trial
Wave said the FDA aligned with a single two-year registrational trial for WVE-006 in alpha-1 antitrypsin deficiency. A one-year interim analysis based on biomarkers could support potential accelerated approval, while the full trial is intended to support a regular approval path.
The same FDA feedback supports Wave's current LC-MS assay for measuring M-AAT and Z-AAT proteins, according to GlobeNewswire. Wave also plans to share data from the 600 mg monthly multidose cohort in the fourth quarter of 2026.
Revenue missed the Q2 estimate
The regulatory progress contrasts with a weaker recent income statement. In Q2 2026, Wave reported revenue of USD 2.27 million against an analyst estimate of USD 7.65 million, while adjusted EPS was a loss of USD 0.34 versus a consensus loss of USD 0.30, according to Investing.com.
Wave's cash and cash equivalents stood at USD 368.0 million on June 30, 2026, while quarterly operating cash flow was negative USD 53.6 million. The figures make clinical execution and financing discipline important counterweights to the potential value of the WVE-006 pathway.
Analysts keep a bullish consensus
H.C. Wainwright reiterated a Buy rating and maintained a USD 13.00 price target on October 2, 2026, according to Investing.com. A separate consensus overview cited by MarketBeat showed a Moderate Buy rating from 17 research firms and an average 12-month target of USD 22.31.
Wave Life Sciences stock stays near its yearly low
Wave Life Sciences stock had a market capitalization of USD 744.8 million on October 2, 2026. Its 52-week range was USD 3.56 to USD 21.73, putting the last price only USD 0.22 above the yearly low; volume reached 3,745,021 shares.
Wave Life Sciences stock facts
- Company: Wave Life Sciences Ltd.
- ISIN: US94352A1043
- Ticker: WVE
- Trading venue: Nasdaq
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 3.78
- Market capitalization: USD 744.8 million (as of October 2, 2026)
- 52-week range: USD 3.56-21.73 (as of October 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
More news and analysis on Wave Life Sciences stock
